Wang Rui, Chen Xianmeng, Xu Shicheng, Jiang Xianliang, Liu Jinli, Liu Xuehan, Ryu Jay H, Hu Xiaowen
Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China.
WanNan Medical College, Wuhu, China.
Orphanet J Rare Dis. 2025 Feb 11;20(1):69. doi: 10.1186/s13023-025-03587-6.
To investigate the prevalence and recurrence rates of spontaneous pneumothorax (SP) in patients with diffuse cystic lung diseases (DCLDs).
We retrospectively identified and analyzed medical records of patients with DCLDs encountered at the First Affiliated Hospital of University of Science and Technology of China from Jan 1, 2017 to December 31, 2023.
A total of 289 patients were identified with DCLDs; 212 females and 77 males, with a median age of 48 years (range, 18-81 years). Among them, 89 (31%) patients had experienced SP; 59% among 115 patients with Birt-Hogg-Dubé (BHD), 34% of 41 patients with lymphangioleiomyomatosis (LAM, all women), 36% of 11 patients with pulmonary Langerhans cell histiocytosis (PLCH), none of 57 patients with Sjögren's syndrome-associated diffuse cystic lung disease (SS-DCLD), and 5% of 65 patients with no identifiable underlying disease (χ² = 90.585, P < 0.001). The overall recurrence rate of SP was higher with observation or chest tube placement strategy compared to surgical intervention, 59% vs. 11% (P < 0.001, 95% CI [0.1, -0.4]), respectively. The recurrence rate after surgical management was significantly lower compared to conservative management in patients with BHD (10% vs. 69%, P < 0.001, 95% CI [0.1, 0.3]) and LAM (20% vs. 57%, P = 0.322, 95% CI [0.1, 2.1]). Among patients with BHD, LAM, and PLCH, those who had pneumothorax as the initial presentation were diagnosed of their underlying disease at a significantly younger age (42.2 ± 13.0 years) compared to those without pneumothorax (48.1 ± 11.8 years) (P = 0.032, 95% CI [-8.24, -0.36]). Notably, eight of LAM patients who were treated with sirolimus after the initial SP did not experience recurrence of SP.
The risk of SP secondary to DCLDs was highest in patients with BHD, followed by those with PLCH and LAM. It was extremely low in SS-DCLD. Pneumothorax as the initial presentation often facilitated diagnosis of the underlying disease. Surgical treatment was associated with a lower recurrence rate of SP compared to nonsurgical management. In addition, sirolimus therapy may reduce the risk of pneumothorax recurrence in patients with LAM.
研究弥漫性囊性肺疾病(DCLD)患者自发性气胸(SP)的患病率和复发率。
我们回顾性地识别并分析了2017年1月1日至2023年12月31日在中国科学技术大学附属第一医院遇到的DCLD患者的病历。
共识别出289例DCLD患者;其中女性212例,男性77例,中位年龄为48岁(范围18 - 81岁)。其中,89例(31%)患者曾发生过SP;在115例Birt-Hogg-Dubé(BHD)患者中,59%发生过SP;41例淋巴管平滑肌瘤病(LAM,均为女性)患者中,34%发生过SP;11例肺朗格汉斯细胞组织细胞增多症(PLCH)患者中,36%发生过SP;57例干燥综合征相关弥漫性囊性肺疾病(SS-DCLD)患者中无人发生过SP;65例无明确基础疾病的患者中,5%发生过SP(χ² = 90.585,P < 0.001)。与手术干预相比,采用观察或胸腔置管策略时SP的总体复发率更高,分别为59%和11%(P < 0.001,95% CI [0.1, -0.4])。在BHD患者(10% vs. 69%,P < 0.001,95% CI [0.1, 0.3])和LAM患者(20% vs. 57%,P = 0.322,95% CI [0.1, 2.1])中,手术治疗后的复发率明显低于保守治疗。在BHD、LAM和PLCH患者中,以气胸为首发表现的患者被诊断出基础疾病时的年龄(42.2 ± 13.0岁)显著低于无气胸的患者(48.1 ± 11.8岁)(P = 0.032,95% CI [-8.24, -0.36])。值得注意的是,8例初始SP后接受西罗莫司治疗的LAM患者未发生SP复发。
继发于DCLD的SP风险在BHD患者中最高,其次是PLCH和LAM患者。在SS-DCLD中极低。气胸作为首发表现往往有助于基础疾病的诊断。与非手术治疗相比,手术治疗与SP的较低复发率相关。此外,西罗莫司治疗可能降低LAM患者气胸复发的风险。